File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor

TitleTreatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor
Authors
Issue Date2003
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm
Citation
Annals Of Hematology, 2003, v. 82 n. 9, p. 548-551 How to Cite?
AbstractFive lymphoma patients relapsed from allogeneic hematopoietic stem cell transplantation (HSCT). Three patients who received myeloablative conditioning had full donor chimerism at relapse, whereas two who received nonmyeloablative conditioning had partially or completely lost the graft. All received mini-BEAM [carmustine (BCNU), etoposide, cytarabine (AraC), melphalan], followed by infusion of HSC (four peripheral blood, one marrow) from the initial donor. Neutropenia and thrombocytopenia were brief, and full donor chimerism was established in all cases. There were four complete and one partial remissions. Graft-versus-host disease occurred in three cases, all with full donor chimerism at relapse. Two patients died subsequently of disease relapse or progression. Another two patients died from fungal infection, one of whom was still in remission at death. One patient had remained in remission 47 months after treatment. Mini-BEAM/HSC is an effective treatment for lymphoma relapses after allogeneic HSCT, but optimal strategies of remission consolidation and prevention of treatment-related complications are needed to improve outcome.
Persistent Identifierhttp://hdl.handle.net/10722/77923
ISSN
2015 Impact Factor: 3.022
2015 SCImago Journal Rankings: 1.117
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorSiu, LLPen_HK
dc.contributor.authorChan, ECen_HK
dc.contributor.authorOoi, GCen_HK
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:37:14Z-
dc.date.available2010-09-06T07:37:14Z-
dc.date.issued2003en_HK
dc.identifier.citationAnnals Of Hematology, 2003, v. 82 n. 9, p. 548-551en_HK
dc.identifier.issn0939-5555en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77923-
dc.description.abstractFive lymphoma patients relapsed from allogeneic hematopoietic stem cell transplantation (HSCT). Three patients who received myeloablative conditioning had full donor chimerism at relapse, whereas two who received nonmyeloablative conditioning had partially or completely lost the graft. All received mini-BEAM [carmustine (BCNU), etoposide, cytarabine (AraC), melphalan], followed by infusion of HSC (four peripheral blood, one marrow) from the initial donor. Neutropenia and thrombocytopenia were brief, and full donor chimerism was established in all cases. There were four complete and one partial remissions. Graft-versus-host disease occurred in three cases, all with full donor chimerism at relapse. Two patients died subsequently of disease relapse or progression. Another two patients died from fungal infection, one of whom was still in remission at death. One patient had remained in remission 47 months after treatment. Mini-BEAM/HSC is an effective treatment for lymphoma relapses after allogeneic HSCT, but optimal strategies of remission consolidation and prevention of treatment-related complications are needed to improve outcome.en_HK
dc.languageengen_HK
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htmen_HK
dc.relation.ispartofAnnals of Hematologyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - administration & dosageen_HK
dc.subject.meshCarmustine - administration & dosageen_HK
dc.subject.meshCytarabine - administration & dosageen_HK
dc.subject.meshEtoposide - administration & dosageen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGraft vs Host Disease - epidemiologyen_HK
dc.subject.meshGraft vs Tumor Effecten_HK
dc.subject.meshHematopoietic Stem Cell Transplantationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLymphoma - therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMelphalan - administration & dosageen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNeutropenia - epidemiologyen_HK
dc.subject.meshRecurrenceen_HK
dc.subject.meshRemission Inductionen_HK
dc.subject.meshThrombocytopenia - epidemiologyen_HK
dc.subject.meshTomography, X-Ray Computeden_HK
dc.subject.meshTransplantation Chimeraen_HK
dc.subject.meshTransplantation Conditioningen_HK
dc.subject.meshTransplantation, Homologousen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleTreatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donoren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0939-5555&volume=82&issue=9&spage=548&epage=551&date=2003&atitle=Treatment+of+lymphoma+relapses+after+allogeneic+hematopoietic+stem+cell+transplantation+with+intensive+chemotherapy+followed+by+infusion+of+hematopoietic+stem+cell+from+the+original+donoren_HK
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityLeung, AYH=rp00265en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00277-003-0696-zen_HK
dc.identifier.pmid14504811-
dc.identifier.scopuseid_2-s2.0-0141840640en_HK
dc.identifier.hkuros87672en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0141840640&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume82en_HK
dc.identifier.issue9en_HK
dc.identifier.spage548en_HK
dc.identifier.epage551en_HK
dc.identifier.isiWOS:000185257100003-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLie, AKW=24284842400en_HK
dc.identifier.scopusauthoridSiu, LLP=35574705900en_HK
dc.identifier.scopusauthoridChan, EC=7401994120en_HK
dc.identifier.scopusauthoridOoi, GC=7006176119en_HK
dc.identifier.scopusauthoridLeung, AYH=7403012668en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats